Skip to main content

vTv Therapeutics Inc.

corporate_fare Company Profile

vTv Therapeutics Inc.

VTVT·NASDAQ·Life Sciences·CIK 0001641489

vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases. The company's primary goal is to improve patient outcomes. Its lead product candidate is cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA). Cadisegliatin is currently in a Phase 3 clinical trial, known as the Cadisegliatin as Adjunctive Therapy to Insulin in Participants with Type 1 Diabetes ("CATT1") trial. This trial is evaluating cadisegliatin as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). The CATT1 Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study designed to assess cadisegliatin's effect on hypoglycemia outcomes in T1D patients. The primary endpoint is the reduction in the frequency of Level 2 hypoglycemia (blood glucose <54 mg/dL) and Level 3 (severe) hypoglycemia over a six-month treatment period. A key secondary endpoint is the change in hemoglobin A1c (HbA1c), a standard measure of glycemic control, to evaluate cadisegliatin's potential to reduce hyperglycemia. The CATT1 trial will randomize 150 patients with T1D on a 1:1:1 basis, with 50 patients per study arm, to receive either 800 mg cadisegliatin daily, 800 mg cadisegliatin twice daily, or placebo. In 2021, the FDA granted Breakthrough Therapy designation for cadisegliatin as an adjunctive therapy to insulin for the treatment of T1D. This designation aims to expedite the development and review of drugs for serious conditions where preliminary clinical evidence suggests substantial improvement over available therapies on clinically significant endpoints. The Breakthrough Therapy designation for cadisegliatin in T1D was supported by positive results from the Phase 2 SimpliciT-1 Study. This multi-center, randomized, double-blind, adaptive study assessed the safety and efficacy of cadisegliatin as an adjunct to insulin therapy in adults with T1D. In that trial, cadisegliatin treatment led to a clinically meaningful 40% decrease in the frequency of severe and symptomatic hypoglycemia and a statistically significant improvement in HbA1c relative to placebo. Cadisegliatin also demonstrated a favorable safety profile, with abnormal levels of serum or urine ketones detected less frequently in patients taking cadisegliatin compared to those taking placebo.

vTv Therapeutics Inc. (NASDAQ:VTVT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for VTVT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-07, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for VTVT spans 8-K, 10-Q, 10-K.

Recent high-impact activity:

  • FDA Grants Orphan Drug Designation to vTv's HPPD for Sickle Cell Disease
  • vTv Therapeutics Swings to $1.05/Shr Loss in Q2 After Q1 Profit
  • vTv Therapeutics Stockholders Express Significant Dissent on Director Elections and Executive Pay
  • vTv Therapeutics Expands ATM Program to Full $47.5M Capacity, Allowing Significant Potential Dilution
  • vTv Therapeutics Reports Strong Q1 Profit and Boosted Cash from Licensing Deals

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$26.97M
Op. Cash Flow
-$25.25M
Operating Income
-$32.81M
Cash & Equivalents
$88.93M
Debt / Equity
0.00×
Source: 10-K · filed 2026-03-10 · accession 0001641489-26-000010

Short Interest & Short Volume

8.21 days to cover

FINRA reported short interest of 145,417 shares in VTVT as of the October 30, 2026 settlement, a 1.4% increase from the prior period — about 8.2 days to cover at its recent average daily volume. On November 20, 2026, 68.3% of VTVT volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)145,417 shares as of October 30, 2026
Change vs prior period▲ 1.4%
Days to cover8.21 at avg daily volume of 17,705
Daily short volume (FINRA facilities)68.3% of 2,013 shares on November 20, 2026
5-day average short volume65.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with V →
$15.51
52-week range · as of 2026-06-29 $14 – $44
Market cap
$61.33M
Volume
10.6K (0.5× avg)
3-mo avg 21.8K
Live data · 2026-11-21 05:57 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed VTVT - Latest Insights

VTVT
Oct 07, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $31.01
Real-time Price: $15.51 info
Change: -$15.50 (-50%) info
Market Cap: $61.327M info
VTVT
Aug 06, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $36.00
Real-time Price: $15.51 info
Change: -$20.49 (-57%) info
Market Cap: $61.327M info
VTVT
Jun 29, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.27
Real-time Price: $15.51 info
Change: -$20.76 (-57%) info
Market Cap: $61.327M info
VTVT
May 13, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.67
Real-time Price: $15.51 info
Change: -$16.16 (-51%) info
Market Cap: $61.327M info
VTVT
May 13, 2026, 4:21 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $31.67
Real-time Price: $15.51 info
Change: -$16.16 (-51%) info
Market Cap: $61.327M info
VTVT
May 13, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $31.67
Real-time Price: $15.51 info
Change: -$16.16 (-51%) info
Market Cap: $61.327M info
VTVT
Mar 10, 2026, 4:37 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.02
Real-time Price: $15.51 info
Change: -$19.51 (-56%) info
Market Cap: $61.327M info
VTVT
Mar 10, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $35.02
Real-time Price: $15.51 info
Change: -$19.51 (-56%) info
Market Cap: $61.327M info
VTVT
Mar 10, 2026, 4:32 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $35.02
Real-time Price: $15.51 info
Change: -$19.51 (-56%) info
Market Cap: $61.327M info
VTVT
Feb 02, 2026, 4:18 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $38.31
Real-time Price: $15.51 info
Change: -$22.80 (-60%) info
Market Cap: $61.327M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets